Non-Insulin Diabetes Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, UK, India - Size and Forecast 2024-2028

Non-insulin Diabetes Therapeutics Market Size 2024-2028

The non-insulin diabetes therapeutics market size is forecast to increase by USD 39.72 billion and is estimated to grow at a CAGR of 12.17% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of type 2 diabetes worldwide. According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. Innovations in therapies, including the development of new classes of non-insulin diabetes drugs and combination therapies, are driving market growth. However, safety concerns regarding diabetes therapeutics, such as the potential for adverse effects and drug interactions, remain a challenge for market players. Additionally, the rising cost of diabetes care and the need for long-term management of the condition are key factors influencing market dynamics. No single medication addresses all seven organs and tissues. Most people require more than one medication to treat the disease. Overall, the market is expected to grow at a pace in the coming years, driven by the increasing number of diabetes patients, innovative therapies, and the unmet need for safe and effective treatment options.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Dynamics and Customer Landscape

The Market encompasses various drugs used for managing Type 2 diabetes, including DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Offline and online channels cater to the distribution of these drugs, with hospital pharmacies and retail pharmacies being the primary outlets. Innovations in therapies, such as strategic alliances and combination drugs, are driving market growth. The market is segmented by Drug Class into Insulin, DPP-4 Inhibitors, and others. Type 1 Diabetes is not included in this market. Routes of administration include insulin injections and oral medications. FDA approval is crucial for market entry. Continuous Glucose Monitoring, Diabetes Treatment, Metformin, Biosimilar Insulin, Diabetes Devices, and Therapeutic Innovation are key components of diabetes care. Glycemic control is the primary goal of diabetes treatment. Hospital Pharmacy Dominance is a trend, but e-commerce and patient awareness are also influencing the market. Incretins, such as GLP-1 receptor agonists, are essential in glycemic control. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

An increasing number of people with type 2 diabetes is the key factor driving the growth of the global market. Type 2 diabetes is caused by the ineffective use of insulin produced by the body. It is the most common form of diabetes worldwide. Obesity and lack of exercise are the most common causes of type 2 diabetes. Type 2 diabetes is caused by hyperglycemia and metabolic changes due to abnormal insulin secretion and action. Until the early 2000s, the disease was common only in adults. However, the prevalence of type 2 diabetes in children is increasing.

Moreover, the early diagnosis of type 2 diabetes is often a challenge due to the generic symptoms associated with the disease. Hence, once the disease is diagnosed, it is essential to provide advanced medications. Different antihyperglycemic drugs are used alone or in combination with other drugs, such as insulin, to treat type 2 diabetes. The initial steps of treatment include weight loss plans, lifestyle changes, and the administration of metformin. The ADA and the European Association for the Study of Diabetes (EASD) recommend a patient-specific treatment approach to enhance glycemic control to treat type 2 diabetes. This is to avoid weight gain and hypoglycemia. Hence, the increasing number of people with type 2 diabetes will drive the growth of the global market during the forecast period.

Significant Market Trends

Innovations in therapies are the primary trend shaping the global market growth. Several companies are introducing advanced therapies to treat diabetes. Incretins are GLP-1 and glucose-dependent insulinotropic polypeptides (GIP), which are secreted by the GI tract in response to food intake. Both GLP-1 and GIP stimulate the beta cells of the pancreas, which contribute 60% of the insulin secreted after a meal. Type 2 diabetes reduces the secretion of GLP-1 and reduces responsiveness to GIP. The benefits of incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release. Two incretin-based drug classes are used to treat people with type 2 diabetes. These include oral DPP4 inhibitors and GLP-1 receptor agonists.

Moreover, the pathophysiology of type 2 diabetes involves at least seven organs and tissues, which include the brain, liver, pancreas, intestines, kidneys, fat, and muscles. Hence, drugs with unique and complementary MoA are required. Therapeutics such as DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, colesevelam, and bromocriptine QR provide therapeutic options with novel MoA. They also prevent weight gain and reduce the risk of hypoglycemia. Though all medications are not appropriate for all people, they offer healthcare providers options to individualize treatments and optimize care for patients. Hence, the market is expected to grow during the forecast period.

Major Market Challenge

Concerns about safety are a major challenge to the growth of the global market. Several non-insulin diabetes drugs are currently under review by the US FDA due to safety concerns. For example, in 2017, the U.S. Food and Drug Administration added a boxed warning to the label of Janssen type 2 diabetes medication because it increases the risk of leg and foot amputations. That's why the company's type 2 diabetes medications like Invokana, Invokamet, and Invokamet XR should include a risk statement in the box next to the canagliflozin drug label.

However, in 2015, the US FDA also revised the labels of SGLT2 inhibitors to include warnings about the risk of high levels of acid in the blood and the possibility of severe urinary tract infections (UTIs). Such initiatives are increasing awareness about the safety of certain drugs. However, they are a challenge for the growth of the global market as companies must make significant investments in R&D to develop safe drugs. Hence, safety concerns may hamper the growth of the market during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abbott Laboratories: The company offers non insulin diabetes therapeutics solutions such as Abbotts Freestyle libre system significantly reduces HBA1C levels in people with type 2 diabetes.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• AstraZeneca PLC
• Better Therapeutics Inc.
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson and Johnson Services Inc.
• Merck KGaA
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• The Cleveland Clinic Foundation

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Market?

The market share growth by the DPP4 inhibitors segment will be significant during the forecast period. DPP4 inhibitors are therapeutics that reduce high blood glucose levels. They are widely used to treat type 2 diabetes. DPP4 inhibitors improve blood glucose control and reduce fasting and postprandial blood glucose levels without causing weight gain. The changes of hypoglycemia are low when using DPP4 inhibitors unless they are combined with other therapies that cause hypoglycemia.

Get a glance at the market contribution of various segments View the PDF Sample

The DPP4 inhibitors segment was valued at USD 12.85 billion in 2018 and continued to grow until 2022. DPP4 inhibitors block the action of DPP4, an enzyme that destroys incretin. As incretin helps the body produce more insulin when needed and reduces the amount of glucose produced by the body when not required, its destruction could cause type 2 diabetes. These hormones are released throughout the day, and their levels increase during the consumption of food. Therefore, DPP4 inhibitors are required to stabilize type 2 diabetes. Hence, their adoption is high across the world. Such factors will increase segment growth during the forecast period.

Which are the Key Regions for the Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Several companies offer non-insulin diabetes therapeutics in North America, which is increasing awareness and the availability of non-insulin diabetes therapeutics in the region. The companies are focusing on product development and clinical trials. Hence, the availability of advanced therapeutics and delivery techniques is improving in the region. However, several stringent regulations have been implemented in the region. For instance, in 2008, the US FDA published guidance for the industry, which recommended that new drug applications (NDAs) for diabetes should include evidence that they do not increase the risk of cardiovascular events. Hence, companies must make significant investments in R&D to develop therapeutics that are safe. Such factors are expected to drive the growth of the regional market during the forecast period.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.

• Type Outlook
  • DPP4 inhibitors
  • GLP-1 receptor agonists
  • SGLT2 inhibitors
  • Others

• Distribution Channel Outlook
  • Offline
  • Online

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Argentina
    • Australia
    • Rest of the world

Market Analyst Overview

The Market encompasses various treatments for Type 2 Diabetes, including DPP-4 Inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. DPP-4 Inhibitors, such as Sitagliptin and Saxagliptin, help lower blood glucose levels by inhibiting the DPP-4 enzyme. GLP-1 receptor agonists, like Exenatide and Liraglutide, stimulate insulin secretion and suppress glucagon production. SGLT2 inhibitors, such as Canagliflozin and Empagliflozin, work by increasing urinary glucose excretion. Innovations in therapies have led to strategic alliances and the development of combination drugs. The market is segmented by Drug Class, Route of Administration (Oral, Subcutaneous, and Intravenous), and Sales Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies).

Moreover, FDA Approval plays a crucial role in the Diabetes Treatment market, with Metformin, Biosimilar Insulin, and Diabetes Devices being commonly used. Patient awareness, Obesity, Sedentary Lifestyle, and Chronic Metabolic Disease contribute to the rising Diabetes Prevalence. The Drug Approval Process, Health Insurance, and Diabetes Population also influence market growth. Therapeutic Innovation in the form of Incretins and Glycemic Control continues to drive the market forward. E-commerce and Hospital Pharmacy Dominance are key trends in the Market. Blood Glucose Levels remain a significant concern for Diabetes patients, making effective and accessible treatments essential. Smart technologies and Artificial Intelligence are revolutionizing Diabetes management with advancements in Machine Learning. For those using Multiple Daily Injections, innovative products from companies like Tandem Diabetes Care, Medtronic, and Insulet Corporation offer new solutions. Despite these advancements, the high cost of these technologies poses challenges to accessibility. Retail & online pharmacy options are expanding, yet healthcare spending remains a significant concern. As Smart technologies continue to evolve, they promise more efficient Diabetes management solutions, but balancing innovation with affordability and accessibility is crucial for broad adoption.

View PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2023 and 2028.
• Precise estimation of the market size and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch